The role of the prion protein in the internalization of α-synuclein amyloids

References

• Kovacs GG. Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine. Int J Mol Sci. 2016;17:189. doi:10.3390/ijms17020189
   PubMed Web of Science ®Google Scholar
• Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001;2:492–501. doi:10.1038/35081564.
   PubMed Web of Science ®Google Scholar
• Kostylev MA, Kaufman AC, Nygaard HB, et al. Prion-protein-interacting amyloid-beta oligomers of high molecular weight are tightly correlated with memory impairment in multiple alzheimer mouse models. J Biol Chem. 2015;290:17415–38. doi:10.1074/jbc.M115.643577.
   PubMed Web of Science ®Google Scholar
• Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends in neurosciences. 2010;33:317–25. doi:10.1016/j.tins.2010.04.003.
   PubMed Web of Science ®Google Scholar
• Luk KC, Song C, O'Brien P, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A. 2009;106:20051–6. doi:10.1073/pnas.0908005106.
   PubMed Web of Science ®Google Scholar
• Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72:57–71. doi:10.1016/j.neuron.2011.08.033.
   PubMed Web of Science ®Google Scholar
• Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009;106:13010–5. doi:10.1073/pnas.0903691106.
   PubMed Web of Science ®Google Scholar
• Le NT, Narkiewicz J, Aulic S, Salzano G, et al. Synthetic prions and other human neurodegenerative proteinopathies. Virus Res. 2015;207:25–37. doi:10.1016/j.virusres.2014.10.020.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Bae EJ, Lee SJ. Extracellular alpha–synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol. 2014;10:92–8. doi:10.1038/nrneurol.2013.275.
   PubMed Web of Science ®Google Scholar
• Tyson T, Steiner JA, Brundin P. Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. J Neurochem. 2016;139(Suppl 1):275–89. doi:10.1111/jnc.13449.
   PubMedGoogle Scholar
• Zhu S, Victoria GS, Marzo L, et al. Prion aggregates transfer through tunneling nanotubes in endocytic vesicles. Prion. 2015;9:125–35. doi:10.1080/19336896.2015.1025189.
   PubMed Web of Science ®Google Scholar
• Abounit S, Wu JW, Duff K, et al. Tunneling nanotubes: A possible highway in the spreading of tau and other prion-like proteins in neurodegenerative diseases. Prion. 2016;10:344–51. doi:10.1080/19336896.2016.1223003.
   PubMed Web of Science ®Google Scholar
• Abounit S, Bousset L, Loria F, et al. Tunneling nanotubes spread fibrillar alpha-synuclein by intercellular trafficking of lysosomes. EMBO J. 2016;35:2120–38. doi:10.15252/embj.201593411.
   PubMed Web of Science ®Google Scholar
• Mao X, Ou MT, Karuppagounder SS, et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science (New York, NY). 2016;353: doi:10.1126/science.aah3374.
   Google Scholar
• Holmes BB, DeVos SL, Kfoury N, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 2013;110:E3138–47. doi:10.1073/pnas.1301440110.
   PubMed Web of Science ®Google Scholar
• Aulic S, Masperone L, Narkiewicz J, et al. Alpha-Synuclein Amyloids Hijack Prion Protein to Gain Cell Entry, Facilitate Cell-to-Cell Spreading and Block Prion Replication. Sci Rep. 2017;7:10050. doi:10.1038/s41598-017-10236-x.
   PubMed Web of Science ®Google Scholar
• Zahn R, Liu A, Luhrs T, et al. NMR solution structure of the human prion protein. Proc Natl Acad Sci U S A. 2000;97:145–50. doi:10.1073/pnas.97.1.145.
   PubMed Web of Science ®Google Scholar
• del Rio JA, Gavin R. Functions of the cellular prion protein, the end of Moore's law, and Ockham's razor theory. Prion. 2016;10:25–40. doi:10.1080/19336896.2015.1126038.
   PubMed Web of Science ®Google Scholar
• Gasperini L, Meneghetti E, Pastore B, et al. Prion protein and copper cooperatively protect neurons by modulating NMDA receptor through S-nitrosylation. Antioxid Redox Signal. 2015;22:772–84. doi:10.1089/ars.2014.6032.
   PubMed Web of Science ®Google Scholar
• Lauren J, Gimbel DA, Nygaard HB, et al. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457:1128–32. doi:10.1038/nature07761.
   PubMed Web of Science ®Google Scholar
• Barry AE, Klyubin I, Mc Donald JM, et al. Alzheimer's disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2011;31:7259–63. doi:10.1523/JNEUROSCI.6500-10.2011.
   PubMed Web of Science ®Google Scholar
• Kessels HW, Nguyen LN, Nabavi S, et al. The prion protein as a receptor for amyloid-beta. Nature. 2010;466:E3–4. discussion E-5. doi:10.1038/nature09217.
   PubMed Web of Science ®Google Scholar
• Urrea L, Segura-Feliu M, Masuda-Suzukake M, et al. Involvement of Cellular Prion Protein in alpha-Synuclein Transport in Neurons. Mol Neurobiol. 2017. doi:10.1007/s12035-017-0451-4.
   Web of Science ®Google Scholar
• Ferreira DG, Temido-Ferreira M, Miranda HV, et al. Alpha-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B. Nat Neurosci. 2017;20:1569–79. doi:10.1038/nn.4648.
   PubMed Web of Science ®Google Scholar
• Um JW, Nygaard HB, Heiss JK, et al. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci. 2012;15:1227–35. doi:10.1038/nn.3178.
   PubMed Web of Science ®Google Scholar
• Colby DW, Prusiner SB. Prions. Cold Spring Harbor Perspectives in Biology. 2011;3:a006833. doi:10.1101/cshperspect.a006833.
   PubMed Web of Science ®Google Scholar
• Haik S, Privat N, Adjou KT, et al. Alpha-synuclein-immunoreactive deposits in human and animal prion diseases. Acta Neuropathol. 2002;103:516–20. doi:10.1007/s00401-001-0499-z.
   PubMed Web of Science ®Google Scholar
• Westergard L, Turnbaugh JA, Harris DA. A naturally occurring C-terminal fragment of the prion protein (PrP) delays disease and acts as a dominant-negative inhibitor of PrPSc formation. J Biol Chem. 2011;286:44234–42. doi:10.1074/jbc.M111.286195.
   PubMed Web of Science ®Google Scholar
• Ghetti B, Piccardo P, Spillantini MG, et al. Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc Natl Acad Sci U S A. 1996;93:744–8. doi:10.1073/pnas.93.2.744.
   PubMed Web of Science ®Google Scholar
• Ghetti B, Tagliavini F, Masters CL, et al. Gerstmann-Straussler-Scheinker disease. II. Neurofibrillary tangles and plaques with PrP-amyloid coexist in an affected family. Neurology. 1989;39:1453–61. doi:10.1212/WNL.39.11.1453.
   PubMed Web of Science ®Google Scholar